2025高血压4大突破性药物疗法，搞定降压难！

Core Insights - The article discusses significant advancements in hypertension treatment, focusing on new drug developments and their implications for clinical practice [1][19]. Group 1: Shifts in Treatment Focus - The focus of hypertension drug development has shifted from "resistant hypertension" to "uncontrolled hypertension," allowing for earlier intervention in treatment [1][2]. Group 2: Key Drug Developments - Four major advancements in hypertension treatment are highlighted: 1. Aldosterone Synthase Inhibitors: New second-generation inhibitors like Lorundrostat and Baxdrostat show promising clinical results, significantly lowering blood pressure in patients [2][3][7]. 2. Angiotensinogen Inhibitors: Utilizing innovative technologies such as siRNA, drugs like Zilebesiran demonstrate effective long-term blood pressure control [9][10]. 3. Dual Endothelin Receptor Antagonists: Aprocitentan, recently approved by the FDA, effectively treats resistant hypertension with a balanced receptor inhibition approach [12][13][16]. 4. Hypertension Vaccine: The HJY-ATRQβ-001 vaccine, recently approved for clinical trials, represents a novel long-term treatment option for hypertension [17][18]. Group 3: Clinical Implications - The advancements in drug development not only address existing clinical challenges but also reflect a deeper integration of basic research into clinical applications, promising more effective and safer treatment options for hypertension management [19].